

9650 ROCKVILLE PIKE, BETHESDA, MARYLAND 20814-3994
PHONE: 301-530-7178 FAX: 301-571-1816
Web: www.scienceXchange.com/aa

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

AAI NEWSLETTER

PRESIDENT'S MESSAGE

Jonathan Sprent, M.D., Ph.D.

On February 1, 1999 AAI President Jon Sprent and AAI Public Affairs Director Pat White reviewed some NIH budget data and had an informal discussion about what the budget means for individual investigators. Their discussion occurred the day that the Clinton Administration released its FY2000 budget request of 2.1%, a dramatic drop following FY99's 15% increase.

Sprent: What do we know about how NIH is going to spend the \$2 billion, 15% increase that it received in FY99?

White: For NIH, this seems to me to be as good as it gets. In FY99, the NIH is going to fund 9100 Research Project Grants (RPGs); an increase of 1600 new and competing renewal grants over FY98.

Sprent: That's a 22% increase in the number of grants funded. I presume most of them are R01s?

White: That's right. NIH Director Harold Varmus and the individual Institute Directors are putting the bulk of the new resources into the mechanisms that are of greatest interest to basic scientists. Although each institute operates independently, the NIH-wide trend is to increase the number of RPGs that are being paid, and to raise the average cost of a grant from \$255,000 to \$285,000 (including indirect costs). At least for FY99, NIH as a whole is funding more and larger grants.

Sprent: Let's talk about administrative reductions, one of my "pet peeves". I see from some of the NIH budget narratives that NIH wants to implement an 11% increase in the average cost of an RPG for FY99, but I don't quite understand what that means. Does it mean that NIH has embarked on a policy of encouraging institutes to pay close to levels recommended by initial review groups and advisory council or does the 11% increase mean that administrative reductions are going down?

White: NIH documents indicate that about \$220 million has been budgeted to increase the average new grant, and that's where the 11% average increase figure comes from. On the subject of administrative reductions, Varmus has said publicly and repeatedly that he would like to see such cuts come down. But Varmus is adamant that he is not in the business of telling individual institutes how to manage their budgets. So his guidance is merely that: it's hortatory but doesn't have the force of an order. However, if you look back over the past few years, the trend in the size of administrative reductions has been down. But remember that every institute is different. For NIAID, grants paid in the 0-4 percentile will receive a "President's Message" continued on page 5

In This Issue

1. President's Message
2. Focus on Public Affairs
3. Unlocking Our Future: Toward A New National Policy by The Honorable Vern Ehlers
7. NIAID: New Autoimmunity Initiatives
8. Cancer Research Institute Funding Programs
11. AAI Advanced Course in Immunology
11. Web Sites of Interest
13. Members in the News
14. American Museum of Natural History Sponsors Infectious Disease Exhibit
15. In Memoriam
17. Meeting Announcements
22. AAI Membership Application
23. AAI Trainee Membership Application

THE AMERICAN
ASSOCIATION OF
IMMUNOLOGISTS

9650 Rockville Pike
Bethesda, Maryland
20814-3994

Tel: 301-530-7178

Fax: 301-571-1816

Email: infoaai@aai.faseb.org

AAI Homepage:

www.scienceXchange.com/aai

Member Services

Tel: 301-530-7195

Journal of Immunology

Tel: 301-530-7197

Council

President

Jonathan Sprent, MD, PhD

Vice President

Roger M. Perlmutter, MD, PhD

Past President

Charles A. Janeway, Jr., MD

Secretary-Treasurer

J. Donald Capra, MD

Councillors

Philippa Marrack, PhD

James P. Allison, PhD

Paul W. Kincade, PhD

Laurie H. Glimcher, MD

Executive Director

M. Michele Hogan, PhD

Staff

Director of Public Affairs

Patrick White

fpwhite@aai.faseb.org

Business Manager

Tim Markwood

wtmarkwood@aai.faseb.org

Executive Assistant

Michael W. Cuddy

mwcuddy@aai.faseb.org

Membership Services

Lisa McFadden

members@aai.faseb.org

Publications Specialist

Linda Jean Comley

comley@aai.faseb.org

Administrative Assistant

Pamela Booth

pbooth@aai.faseb.org

FOCUS ON PUBLIC AFFAIRS

AAI Members Serve At FASEB Consensus Conference

AAI members Joel Buxbaum and Jeff Frelinger served as delegates to the FASEB Fiscal Year 2000 Federal Funding Consensus Conference, December 8-10, 1998 in Potomac, Maryland. Buxbaum represented AAI on the Department of Veterans Affairs (VA) Medical Research Subcommittee and Frelinger served on the National Institutes of Health (NIH) Funding Subcommittee, working with representatives from other FASEB societies in making consensus recommendations regarding research funding for next fiscal year. Buxbaum's Subcommittee recommended that VA Medical Research receive at least \$360 million in Fiscal Year 2000. Frelinger's NIH Subcommittee (which was chaired by AAI Member Fred Sanfilippo) recommended a 15% increase in NIH funding for FY2000, inaugurating the second year of a five-year campaign to double NIH funding. Frelinger, Sanfilippo and Buxbaum are to be thanked for their hard work on behalf of AAI, FASEB and the biomedical research community.

A highlight of the FASEB Consensus Conference was a presentation by Congressman Vern Ehlers (R-MI), who reported on his work in developing a National Science Policy for the U.S. Congress (see Ehlers below). Ehlers, a physicist who conducted research and taught at Calvin College before entering politics, is one of the few scientists currently serving in Congress and has emerged as a leader on science policy issues. Ehlers prepared “*Unlocking Our Future: Toward a New National Science Policy*” at the request of former House Speaker Newt Gingrich, and intends it as a discussion document for future debate of U.S. science policy and funding priorities. The report is accessible on the web at: http://www.house.gov/science/science_policy_study.htm

Following his remarks, Buxbaum, Frelinger, AAI Executive Director Michele Hogan and Public Affairs Director Pat White chatted with Ehlers, who has attended several AAI Public Affairs activities on Capitol Hill.

Unlocking Our Future: Toward A New National Science Policy

By: The Honorable Vernon J. Ehlers, January 1999

A little more than a year ago, I began, under the auspices of the House of Representatives’ Committee on Science, a major effort to evaluate the Nation’s current science and technology policies and to formulate recommendations for the future. Today’s political, economic and cultural climates are significantly different than those present during the last major analysis of our country’s scientific agenda. Science and technology have heavily influenced those changes, and are likewise subject to them. Our vision for this project was to develop a framework for national science policy development that would allow the United States to maintain and improve its pre-eminent position in the science and technology enterprise in order to advance human understanding of the universe and all it contains. A companion goal of increased understanding is to improve the lives, health and freedom of all peoples.

In preparing the report (*Unlocking Our Future Toward a New National Science Policy*), I spoke with or to many scientists (in both small and large forums), received over 300 emails and numerous letters. In addition, the Science Committee held seven hearings, two roundtable discussions and many other meetings on the subject of the Science Policy Study. We listened very carefully to what every group or individual had to say, and from these conversations made several conclusions i) our Science Policy is outdated; ii) the American public does not understand science or its practice; and iii) scientists overall are politically naïve. The consensus of what we heard was that our nation needs better science, math, engineering and technology education; a new concise, coherent, comprehensive science policy; and civic-minded politically aware scientists.

To begin to deal with these issues, the report makes recommendations in three major areas. First, we must have stable and substantial federal support of basic research. In doing so it is crucial that we balance a diversified research portfolio with topical and burgeoning fields so that we sustain the interdisciplinary synergy that is clearly one of the great strengths of our cumulative scientific endeavor. Secondly, we must encourage active private sector participation in the research process, and not strictly on the development side of the equation. Despite today’s rampant growth of fields such as biotechnology, a significant gap remains overall between basic and applied research. This “Valley of Death”, as I think of it, must be better bridged if we are to sustain the overall scientific and engineering enterprise. Finally, our system of science and mathematics education must be strengthened from kindergarten through graduate school. We depend upon this system to produce the diverse array of individuals that will build our future, from fellow scientists and engineers to technologically-proficient workers to informed voters and consumers.

I have been gratified by the reception the report has received so far. I immediately received letters of support from the Director of the National Science Foundation and from the Office of Science and Technology Policy, as well as from the bipartisan Senate Science and Technology Caucus. Significantly, the report not only gained approval of a majority of the members on the House Science Committee, but also was approved by the full House of Representatives on October 8, 1998. Since its passage, large numbers of scientists and scientific societies have applauded this work.

It is my hope that our report will be seen as a first step, a launching point designed to stimulate discussion about modern science policy and potential implementation measures, and will provide a framework for further study and

action. There is much to be done, and the scientific community has a unique opportunity to impact national policy in a way not seen since the end of World War II. The community as a whole must become more involved in promoting change and communicating with the general public. I encourage each and every one of you to interact with your local, state and federal government representatives, to speak with civic groups, or to get involved in local education activities. By doing one or more of these activities, you will not only be helping to strengthen the scientific enterprise, but also the nation.

Dr. Ehlers was first elected to Congress in a special election in December 1993, after a distinguished career of teaching, scientific research, and community service. The first research physicist to serve in the U.S. Congress, Ehlers serves as Vice Chairman of the House Science Committee. Unlocking Our Future Toward a New National Science Policy is available on the internet at www.house.gov/science/science_policy_study.htm.

We are especially grateful to Laura Lyman Rodriguez, Ph.D., Science Fellow in the office of Congressman Ehlers for her assistance with this article.

Call for Nominations for the Gustav O. Lienhard Award

The Institute of Medicine is accepting nominations for the fourteenth annual Gustav O. Lienhard Award. The award, a medal and \$25,000, recognizes individuals for outstanding achievement in improving health care services in the United States. Support for the award is provided by The Robert Wood Johnson Foundation.

The Gustav O. Lienhard Award focuses on creative or pioneering efforts that have appreciably improved personal health services rather than on contributions to the science of health care. To encourage consideration of the widest possible range of candidates, no eligibility limits are placed on the education and profession of individuals who may be nominated.

Award recipients are selected on the basis of two principal criteria:

- achievement in the area of personal health services, and
- achievement of national scope

Nominations must be postmarked by May 14, 1999.

For additional information, contact:

Ms. Marion Ein Lewin
The Lienhard Award Committee
Institute of Medicine (FO-3114)
2101 Constitution Avenue, N.W.
Washington, D.C. 20418
Phone: (202) 334-1506
Email: hppf@nas.edu

Attention AAI Poster Presenters at EB '99

If you are presenting a poster at EB '99, please note the new presentation time - 12:30-2:30 PM.

“President’s Message” continued from page 1

5% administrative cut, those in the 4.1-8th percentile will see a 7% reduction, and those in the 8.1-20th percentiles will see a 9% cut. NIAID had these same reduction levels for FY98. You recall that about five-plus years ago the administrative reductions at NIAID were much greater; so this is certainly a much better situation. At NCI, FY98 administrative reductions averaged 15%. This is apparently going to come down to around 12% in FY99 and may even go below that.

Sprent: So, will administrative cuts eventually disappear?

White: Unfortunately, probably not. There are several factors at work here but most important is the planning difficulty posed by the NIH appropriation process, that is, the challenge of planning multimillion or billion dollar budgets when next year’s appropriation can’t be predicted. Administrative reductions serve as one way to control the rate of growth in good years and, in bad years, offer an even-handed way of ensuring new individual investigators survive.

Sprent: What about paylines? I am concerned that despite the 22% increase in the number of grants for FY99 and the higher cost for grants, the percentile payline at some institutes is actually coming down.

White: We have to be careful in discussing what a “payline” means. The answer from the institutes is that **success rates** are going up. At NIH broadly, the FY99 projection is for a 33% success rate. NCI projects a success rate of 28% and a percentile payline of 24, which holds steady from FY98. At NIAID, the percentile payline is actually going to come down, from the 24th to the 20th percentile, but the success rate for R01s is projected to be 42%.

Sprent: A lot of us aren’t comfortable with NIH’s use of the term “success rate”. This means little to investigators and only tells us about the ultimate chance of a grant getting funded after up to two resubmissions. For investigators the only hard and meaningful data are the percentile of your grant and the payline at the funding institute.

White: Part of the confusion over this issue is the variability of the definition of success rate. Over time, the trend has been that the success rate has become a more accurate measure for R01s. However, what is figured into the success rate may differ from institute to institute. It is clear that at some institutes grant mechanisms other than RO1’s, that don’t necessarily show up in the payline, get loaded into success rates.

Sprent: I still don’t understand why with a large budget increase, the percentile payline is actually coming down at NIAID.

White: Part of the answer is that NIAID is receiving disproportionately *more* applications than other institutes and expects to pay *more* grants that have *larger budgets* in FY99 versus FY98. To think about it another way, if NIAID is receiving more applications with bigger budgets, in order to pay the same number of grants in FY99 as in FY98, the payline would have to come down.

Also, NIAID is very concerned about the “frontloading” of commitments in a given year: this year’s grants become next year’s base. If you pay as many RO1’s this year as you possibly can, and next year’s NIH appropriation is the same or less, you jeopardize your ability to pay new grants that year. NIAID is trying to avoid the “roller-coaster” effect in multi-year budgeting. Remember when the payline was at the 10th percentile? The NIAID is trying to prevent that from happening again.

Sprent: We also had some bad news from the Administration today. The Clinton Administration’s FY2000 request is for a 2.1% increase for the NIH. The Administration has chosen not to follow the Congress’ lead in doubling the NIH budget in five years.

White: It’s only \$320 million compared to a \$2 billion increase for the current year.

Sprent: And new grants will fall by 1500 in FY2000, from this year’s 9100 to about 7600. They’re not even willing to fund a steady state. That’s disastrous. What’s behind it?

“President’s Message” continued on page 6

“President’s Message” continued from page 5

White: We face two major challenges, one is management and the other is politics. On the management side, the White House Office of Management and Budget (OMB) and key congressional staff have questioned whether the NIH can absorb 15% increases from year to year.

Sprent: You told us that OMB had said that NIH only deserved a three-tenths of a percent increase for next year.

White: Yes. In the first internal draft of the Administration’s FY2000 budget, OMB recommended a \$48 million increase for next year, citing concerns about a “serious degradation of research productivity” because of doubts about NIH’s ability to absorb and manage such a large increase in FY99. At the same time, NIH champions such as Senators Pete Domenici (R-NM) and Tom Harkin (D-IA) have also begun to ask tough questions about accountability and oversight. And that is as it should be. We have to be mindful that with success comes accountability.

And this brings us to the political challenge. Because NIH has done so well, it becomes an outlier in the federal budget, and invites all kinds of scrutiny. And there are many factors at work here. Despite the current federal budget surplus, other lobbying groups (say, for education or public health) argue that NIH’s success has come at the expense of other, equally deserving, programs. Also, technical staff in Congress and in the executive branch have seen other agencies (for example the Pentagon in the 80’s) fail in the management of huge infusions of dollars. And politically, there is a question that there is enough worthwhile science to fund.

But perhaps the main political factor is that the Administration is betting that there is no way NIH’s Congressional champions will let this stand. And so a low number for NIH gives them a bargaining chip with Congress. Senator Arlen Specter (R-PA) and Congressman John Porter (R-IL) will want to give NIH a healthy increase, but they will have to agree to more spending for favored Administration programs to get it.

And too, the Administration is taking the position that the 15% increase that Congress gave NIH last year was two years’ money in one. Last year, during his State of the Union Address, the President committed to giving NIH a 50% increase over five years. So the attitude is that 15% in FY99 and 2% in FY2000 is the right trajectory.

Sprent: So, to boost the 2% increase, it looks as though, once again, all of us need to be ready to press the case for NIH and biomedical research. There will be no rest for Bob Rich and you and the Committee on Public Affairs.

White: I’d ask that AAI members stay tuned and be ready to contact their elected officials at critical points in the upcoming budget fights. I’ll be in touch by email, and will ask you to act only at critical moments. We still have our champions on the Hill, but they will need our help more than ever this year.

RESEARCH GRANTS AVAILABLE FROM THE NATIONAL ALOPECIA AREATA FOUNDATION (NAAF)

The National Alopecia Areata Foundation has received several major donations to support research in 1999, and it is now looking for qualified investigators to submit research grant proposals. Individual grants generally range from \$10,000 to \$50,000. Priority is given to research proposals concerned with the immunology and biology of alopecia areata, the biology and control mechanisms of hair growth, and new treatments for alopecia areata.

The deadline for completed applications is April 15, 1999. The NAAF Medical Advisory Board will consider all applicants and will select the projects to be funded. Approved applications may be funded by mid-summer of 1999. Application forms may be obtained from:

National Alopecia Areata Foundation
710 C Street, Suite 11
San Rafael, CA 94901
Phone 415-456-4644

News Flash from NIAID: Look Out for New Autoimmunity Initiatives

With new money from Congress targeted for autoimmunity, new NIH-wide initiatives have been recently published or are soon to appear in the NIH Guide.

Ten new initiatives are being added to four others which solicit a mix of grants, contracts, cooperative agreements, and centers that NIAID published last spring and summer (see list below). The latest expansion began after Congress gave the Institute \$30 million to expand autoimmune diseases research. NIH director Dr. Harold Varmus asked NIAID to coordinate the development of the initiatives supported, in part, by the additional funds.

In December 1998, representatives from many NIH institutes, centers and divisions completed the initiatives, which support a broad spectrum of cross-cutting research (pathogenesis, genetics, environmental factors, translational and clinical research); accelerate the clinical application of knowledge and technology; and exploit the best disease models.

All initiatives will be published by February with receipt dates beginning in April or May, except for the Hyperaccelerated Award/Mechanisms in Immune Disease Trials RFA, which has monthly receipt dates.

Participating NIH entities include NIEHS, NIAID, NIDDK, NIDCR, NICHD, NINDS, NIAMS, NIMH, NHLBI, NEI and ORWH. (<http://www.niaid.nih.gov>)

NIH Autoimmunity Research Initiatives

Environment/Infection/Gene Interaction in Autoimmunity (R21)
New Imaging Technologies for Autoimmune Disease (R01) Genetic Bases and Molecular Pathways to Target Organ Involvement in Autoimmune Disease (R01)
Genetics of Multiple Autoimmune Diseases - Registry and Repository (N01)
Stem Cell Transplantation for the Treatment of Autoimmune Diseases (N01)
Collaborative Network for Clinical Research on Immune Tolerance Implementation of Autoimmune Disease (N01)
High Throughput Screens for Immunological Phenotyping of Mouse Mutants (R21)
Non-Human Primate Models of Transplantation Tolerance (U19)
Genetics of Autoimmune Diseases - Supplements to Active Registries (N01)
Rat Autoimmune Disease Genetic Resource (supp.)
Pilot/Feasibility Trials on Innovative Therapies for Rheumatic and Skin Diseases (N01)

NIAID Published RFAs

Human Islet Transplantation into Humans (R01)
Hyperaccelerated Award/Mechanisms in Immune Disease Trials (R01)
Clinical Trials and Clinical Markers for Immunologic Diseases (N01)
Autoimmunity Centers of Excellence (U19)
Human Immunology Centers of Excellence (P01)

SPECIAL NOTICE FOR AAI BLOCK SYMPOSIA PRESENTERS!!

ALL ABSTRACTS SELECTED FOR ORAL PRESENTATION ARE ALSO REQUIRED TO BE PRESENTED IN A POSTER SESSION

For block symposia and poster session information please see the Author Index on the EB '99 Website at: <http://www.faseb.org/meetings/eb99>

Cancer Research Institute Funding Programs

PREDOCTORAL EMPHASIS PATHWAY IN TUMOR IMMUNOLOGY

Through the predoctoral pathway, universities and research centers are invited to apply for training grants establishing multi-year programs that support doctoral students interested in pursuing careers in cancer immunology. The grants provide the institution with \$450,000 over a four-year period. There is no set application deadline.

POSTDOCTORAL FELLOWSHIPS

Are designed to foster the training of qualified young immunologists and cancer immunologists at leading universities and research centers around the world. These two- to three-year funding commitments have been raised to \$32,000 in the first year; \$34,000 in the second year, and \$36,000 in the third year. The fellowships also include an institutional allowance of \$1,500 per year. Deadlines are April 1 and October 1.

INVESTIGATOR AWARDS

Support immunologists and cancer immunologists at the assistant professor level as they undertake their first independent investigations. Funds may be used at the recipient's discretion for salary, technical assistance, supplies, or capital equipment. Investigator awards provide \$50,000 a year for four years. The deadline for applications is March 1.

CLINICAL INVESTIGATION PROGRAM

Pre-Clinical Grants and Clinical Trials Grants provide funding for immunological research in the areas of melanoma and prostate cancer. Proposals in areas other than melanoma and prostate cancer will be accepted only in response to a formal call for proposals.

Pre-Clinical Grants fund immunology and cancer immunology laboratory research in human cancers and in animal models of cancer at a level of \$100,000 a year for three years. The application deadline for Prostate Cancer Initiative pre-clinical grants is April 15 and for Melanoma Initiative pre-clinical grants is September 1.

Clinical Trials Grants support Phase I/II clinical trials of new immunotherapies for cancer. These grants provide funding of \$150,000 a year for 3 years. The application deadline for Prostate Cancer Initiative clinical trials grants is April 15 and for Melanoma Initiative clinical trials grants is September 1.

For additional information or applications, please contact Lynne Harmer, Director of Grants Administration, at (212) 688-7515, (212) 832-9376 (FAX), or cancerres@aol.com.

Cancer Research Institute
National Headquarters
681 Fifth Avenue
New York, NY 10022-4209
Web site: www.cancerresearch.org

Summary of Clinical Data Available from ACAAI

Health care professionals and health plan administrators can receive new information on how the involvement of allergists in asthma care improves treatment outcomes and lowers costs. Recent published studies are abstracted and summarized in the booklet *The Role of the Allergist in Cost-Effective Treatment of Asthma* produced by the American College of Allergy, Asthma & Immunology. Single copies of the booklet are available free. Contact:

ACAAI
85 West Algonquin Road
Suite 550
Arlington Heights, IL 60005

Experimental
Biology
99[®]



April 17 - 21, 1999
Washington, DC

AAI'S MEETING PROGRAM IS AVAILABLE ON
THE AAI HOMEPAGE AT:
WWW.SCIENCEXCHANGE.COM/AAI

The American Physiological Society (APS)
American Society for Pharmacology and Experimental
Therapeutics (ASPET)
American Society for Investigative Pathology (ASIP)
American Society for Nutritional Sciences (ASNS)
American Association of Immunologists (AAI)
American Association of Anatomists (AAA)
Guest Societies

For more information contact: Experimental Biology 99
9650 Rockville Pike
Bethesda, MD 20814-3998
Telephone 01/530-7010 Fax: 301/530-7014
Email: eb@faseb.org Web: www.faseb.org

The American Association of Immunologists
Advanced Course in Immunology
The University of California - Berkeley
July 19-24, 1999

Under the direction of the
AAI Education Committee
Abul Abbas, Chairman

For further information
contact Linda Nelson
FAX: (619) 534-5611
Email: linda@biomail.ucsd.edu
(Use subject line: AAI COURSE)

Faculty

Abul Abbas, Harvard University
Rafi Ahmed, Emory University
James Allison, Univ. of California, Berkeley
Leslie Berg, University of Massachusetts
Pamela Bjorkman, Cal. Institute of Technology
Jason Cyster, UCSF
C. Garrison Fathman, Stanford University
Marc Jenkins, University of Minnesota
Katherine Knight, Loyola University
Leo Lefrancois, University of Connecticut
Richard Locksley, UCSF
Mike McCune, UCSF
Elizabeth Mellins, Stanford University
Andrey Shaw, Washington University
Robert Schreiber, Washington University
Megan Sykes, Harvard University

Web Sites of Interest

The AAI lists these web sites as a service to our membership and readership. AAI does not endorse or guarantee the information on the listed sites. If you wish to comment, or offer sites of interest, please contact AAI at infoaai@aai.faseb.org.

EB '99 Meeting Web Site

<http://www.faseb.org/meetings>

SWISS-PROT Annotated Protein Sequence Database

A curated protein sequence database which strives to provide a high level of annotations (such as the description of the function of a protein, its domains structure, post-translational modifications, variants, etc), a minimal level of redundancy and high level of integration with other databases.

<http://expasy.hcuge.ch/sprot>

The National Center for Biotechnology Information Taxonomy Homepage

The NCBI taxonomy database contains the names of all organisms that are represented in the genetic databases with at least one nucleotide or protein sequence.

<http://www.ncbi.nlm.nih.gov/Taxonomy>

Members in the News

Bernard Roizman, Sc.D., Receives Eighth Annual Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Disease Research

Bernard Roizman, Sc.D., the Joseph Regenstein Distinguished Service Professor of Virology at the University of Chicago, is the recipient of the eighth annual Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Disease Research. Roizman received the award for his groundbreaking work in mapping the genome of the herpes simplex virus (HSV), describing how the virus fights host cells, and developing recombinant DNA techniques to determine the role of specific HSV genes in viral replication.

In the late 1950s, Dr. Roizman purified the DNA of HSV and showed that gene sequences in HSV differ in unrelated people, but are identical in related people with the virus. From these genetic fingerprints arose the science of molecular epidemiology --literally, the ability to trace infection from one person to the next --which Dr. Roizman used to demonstrate that nurses in hospital maternity wards were unwittingly transmitting HSV among infants simply by failing to wash their own hands. The findings led to a change in hospital practices and a dramatic decrease in HSV transmission in maternity wards.

Subsequently, Dr. Roizman developed recombinant DNA techniques for inserting and deleting genes into the HSV genome at will. The method, which has since been used to explore gene function in pox viruses, adenoviruses and large DNA insect viruses, enabled Dr. Roizman to discover new genes and to identify the function of genes that enable the virus to block host responses to infection. In manipulating these genes, Dr. Roizman also devised ways to harness HSV's unique survival abilities to fight other diseases. His work has laid direct ground for current efforts to develop a vaccine against HSV, as well as for gene therapies and anticancer treatments that employ altered forms of the virus.

Dr. Roizman's many contributions to science have been recognized by his receipt of the J. Allyn Taylor International Prize in Medicine, the Centennial Medal of the Institut Pasteur, and the first annual ICN International Prize in Virology, as well as honorary doctorates from the University of Ferrara in Italy and the University of Paris, in France. He is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Academy of Microbiology and an Honorary Member of the Hungarian Academy of Sciences. He has been an AAI member since 1959.

Marc Rothenberg Receives 1998 Pharmacia International Award

Marc Rothenberg, M.D., Ph.D., Assistant Professor at the University of Cincinnati and Children's Hospital Medical Center, was awarded the 1998 Pharmacia International Award from the Pharmacia Allergy Foundation. Dr. Rothenberg shares the award with AAI member Dr. Santa Ono (see July/August 1998 newsletter). The annual award, one of the largest individual achievement awards for biomedical scientists under age 40, was given at the 17th International Congress of the Academy of Allergy and Clinical Immunology in Birmingham, England.

Dr. Rothenberg received the award for demonstrating the critical role of chemokines such as eotaxin, MCP-4, and RANTES in the recruitment of eosinophils into the sites of allergic inflammation. He utilized targeted gene deletion in animal models and neutralizing antisera to distinguish the effects of each chemokine and to quantitate their individual contribution.

Besides the Pharmacia International Award, Rothenberg has also been the recipient of the Young Investigator Award and the Scholar in Allergy Award from the American Academy of Allergy, Asthma, and Immunology. He has been an AAI member since 1997.

Francis V. Chisari Receives 1999 Rous-Whipple Award

Francis V. Chisari, M.D., Professor and Head of the Division of Experimental Pathology at the Scripps Research Institute, is the winner of the 1999 Rous-Whipple Award from the American Society for Investigative Pathology (ASIP). He has been invited to present a lecture at the annual meeting of the ASIP at EB '99. The Rous-Whipple award recognizes leading experimental pathologists over age 50 who have had a distinguished research career and are continuing to contribute to the field.

Dr. Chisari is the author of more than 240 papers illuminating the immunobiology and pathogenesis of hepatitis B and C virus infections. In a long series of studies, his group first defined the CD4 and CD8 T-cell response to HBV in infected patients, providing critical insight into the immunological basis of viral clearance and persistence during HBV infection, and establishing the scientific basis for current efforts to develop antigen-specific immunotherapy for chronic hepatitis. His interest in HBV pathogenesis led Dr. Chisari to develop the first transgenic mouse model of a pathogenic human viral infection. Importantly, his group discovered that HBV replication in the liver is abolished noncytopathologically by inflammatory cytokines secreted by CTLs following antigen recognition. This seminal discovery reveals that the immune response can clear certain infections by "curing" as well as by killing infected cells, a tissue-sparing function with obvious survival advantages for the host.

Dr. Mark L. Tykocinski, Chairman of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Health System said Chisari is "an outstanding scientist ... at the cutting edge of Experimental Pathology" whose work "embodies and defines the best of his discipline." Dr. Peter M. Howley, Chairman of the Department of Pathology at Harvard Medical School says Dr. Chisari "has made, and continues to make, fundamental contributions to our understanding of the pathogenesis of hepatitis B virus infections" and calls him "one of the leading scientists in the world in viral pathogenesis."

Dr. Chisari is the Director of the General Clinical Research Center at Scripps, and he has been an Adjunct Professor of Pathology at UCSD for many years. He is a member of the Association of American Physicians, and a fellow of the American Association for the Advancement of Sciences. He has received numerous awards for his work, including the Ernst Jung Prize in Medicine, and the First Distinguished Scientific Achievement Award from the American Liver Foundation. Dr. Chisari has been an AAI member since 1975.

AAI is interested in the achievements of its membership. Please let us know if you have recently received an honor or award, been elected as a member to a prominent society, or have conducted media interviews. Send the information, with a short biography and photo (and a copy of the article/tape for media interviews) to:

Members in the News
American Association of Immunologists
9650 Rockville Pike
Bethesda, MD 20814-3994

American Museum of Natural History Sponsors Infectious Disease Exhibit

The American Museum of Natural History is sponsoring a new exhibit entitled *Epidemic! The World of Infectious Disease*, which will be on display February 27-September 6, 1999. The exhibit explores the biological and ecological factors that influence the causes, spread, and control of infectious diseases, and investigates cultural determinants. The following AAI members served on the Advisory Committee for this exhibit: Barry Bloom, Ph.D., Anthony S. Fauci, M.D., Samuel Katz, M.D., and Mary E. Wilson, M.D. For more information contact The American Museum of Natural History, Central Park West at 79th St., New York, NY 10024-5192. Phone: 212/769-5006, or on the web at www.amnh.org.

Zoltan Ovary, M.D. to Publish New Book: *Souvenirs Around the World in Ninety Years*

AAI member Zoltan Ovary, M.D., the oldest fully-employed immunologist in the world (according to the International Union of Immunological Societies), is the author of the soon to be released *Souvenirs Around the World in Ninety Years*. In this book, Dr. Ovary has written about his lifelong passion for science and the arts, and recalls the many extraordinary people who have shared his passion.

Although now past the age of 90, Dr. Ovary is still a professor and scientist at the New York University Medical School. A pioneer of immunology, he has published more than three hundred articles for professional journals such as *Science*. He is known for his many historical discoveries, among them the Passive Cutaneous Anaphylaxis Reaction, a breakthrough in the study of allergy and the quantitation of antibodies. In 1984, NYU started the annual Zoltan Ovary Symposium to celebrate his work and his inspirational role. Dr. Ovary has been an AAI member since 1957.

For more information on *Souvenirs Around the World in Ninety Years* contact:

India Ink Press
P.O. Box 655
Murray Hill Station
New York, NY 10156-0604
Phone: 212/663-9042 s Fax: 212/263-7533
Email: ovary01@popmail.med.nyu.edu

In Memoriam

John J. Munoz, Ph.D.

John J. "Jack" Munoz, Ph.D., 80, died in Tucson, Arizona, on January 9, 1999. After coming to the United States from his native Guatemala, he studied at Louisiana State University, the University of Kentucky, and in 1947, received a Ph.D. in Medical Bacteriology from the University of Wisconsin in Madison.

From 1957 to 1961 he was Chairman of the Department of Microbiology and Director of the Stella Duncan Memorial Laboratory at the University of Montana in Missoula. In 1961, Dr. Munoz became a Research Microbiologist at the Rocky Mountain Laboratories of the NIAID, and then became the Head of the Allergy and Immunology Section.

His major area of interest was biologically active substances from *Bordetella pertussis* and the role of these components on induction of immunity to whooping cough. He published extensively with colleagues and collaborators world-wide. His tenure at the Rocky Mountain Labs included assignments to the Pasteur Institute in Paris, France and to the Walter and Eliza Hall Institute for Medical Research in Australia. In 1979 he received the National Institute of Health Director's Award for his work in this field. Although his primary field was bacteriology, Dr. Munoz had an abiding interest in pathogenesis of persistent viral diseases. The present Laboratory of Persistent Viral Diseases at Rocky Mountain Labs was founded with scientists who had worked in Dr. Munoz's section.

He retired from the Rocky Mountain Labs on December 30, 1988, after 27 years of service and was appointed Scientist Emeritus from 1989 to 1997. Dr. Munoz had been an AAI member since 1951.

*Submitted by Marshall Bloom, M.D.
NIAID, NIH, Rocky Mountain Labs*

FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY

Executive Director

The Federation of American Societies for Experimental Biology (FASEB) invites applications and nominations for the position of Executive Director to begin service on or after June 1, 1999.

The mission of FASEB is to enhance the ability of biomedical and life scientists to improve, through their research, the health, well-being, and productivity of all people. FASEB is a coalition of independent Member Societies that represents the interests of biomedical and life scientists, particularly those related to public policy issues. FASEB facilitates coalition activities among Member Societies and disseminates information on biological research through scientific conferences and publications. FASEB also offers Member Societies headquarters facilities, and operational and logistic support.

Founded in 1913, FASEB now includes 17 biomedical and life science societies with an aggregate membership of more than 52,000 scientists.

Located on a campus of approximately 11.5 acres in Bethesda, Maryland, the facilities include 128,000 square feet of office accommodation, and a conference center accommodating meetings of up to 150 participants. A plan to explore expansion of the facilities by new construction providing 42,000 additional square feet of office space has been approved.

The Executive Director reports directly to the President and Board of Directors and is the Chief Operating Officer of FASEB providing leadership and direction to approximately 110 professional, technical and clerical support staff, and manages an annual operating budget of approximately \$14 million. The primary responsibilities of the Executive Director include recruitment and direction of key staff; management of resources to ensure required support for the programs and activities of the Member Societies; development of new facilities to ensure that the services provided by FASEB remain at the leading edge of technology; and, maintenance of an effective coalition through liaison with Member Society staffs.

Qualified applicant should have executive/administrative experience in planning and resource allocation with a record of achievement and leadership in management of academic, association or other non-profit organizations. The Executive Director must have the ability to work in a multi-centered environment, a commitment to coalition building, an interest in the applications of technology to the management of associations and familiarity with public policy issues of importance to biomedical and life scientists.

Qualified candidates should send resume with covering letter in confidence by March 15, 1999, to:

William R. Brinkley Ph.D.
FASEB President
Attn: Human Resources
9650 Rockville Pike
Bethesda, MD 20814
FAX: 301-571-0684

To view history, activities, benefits and a complete job description see our web site at:

<http://www.faseb.org>

EOE

MEETING ANNOUNCEMENTS

MARCH

19-22 *Association of Biomolecular Research Facilities Annual Meeting* will be held at the Durham Civic Center in Durham, NC. **Contact:** OSMC, 9650 Rockville Pike, Bethesda, MD 20814-3998.
Phone: 301-530-7009 • Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org

APRIL

8-11 *Workshop on NK T Cells and CD1 Mediated Antigen Presentation* will be held at the Westin Hotel in San Diego, CA. **Contact:** La Jolla Institute for Allergy and Immunology, Attention: Nancy Houghton, 10355 Science Center Dr., San Diego, CA 92121.
Phone: 619-558-3535 • Fax: 619-678-4595
Email: nancy@liai.org or mitch@liai.org
Web: www.liai.org/CD1

15-16 *Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications* will be held at the Natcher Conference Center, NIH, MD.
Web: www.nih.gov

17-21 *EB '99* will be held at the Washington, D.C. Convention Center. **Contact:** EB '99, 9650 Rockville Pike, Bethesda, MD 20814-3998.
Phone: 301-530-7010 • Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org/meetings

21-23 *The 5th National Symposium: Basic Aspects of Vaccines* sponsored by the Walter Reed Army Institute of Research, will be held at the Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD. **Contact:** Olga Mancuso, Dept. Of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
Phone: 202-782-0002 • Fax: 202-782-0721
Email: SYMPOSIUM@WRAIR-EMH1.ARMY.MIL
Web: wrair-www.army.mil/symposia/dmbsym.htm

28-May 1 *The Psychoneuroimmunology Research Society* meeting will be at the Hotel Galvez in Galveston, TX.
Phone: 708-216-6728 • Fax: 708-216-3913
Web: www.urmc.rochester.edu/pnirs/welcome.html

MAY

5 *Regulation of the Immune Response: Mechanisms of Host Defense* presented by the Duke University Arthritis Center, Div. Of Rheumatology, Allergy & Clinical Immunology, Center for AIDS Research, and the Depts. Of Microbiology and Immunology, will be held at the Searle Continuing Education Center, Duke Univ. Medical Center, NC. **Contact:** Duke Office of Continuing Medical Education, Box 3108/PCC 602, Duke Univ. Medical Center, Durham, NC 27710.
Phone: 800-222-9984 • Fax: 919-681-7462

9-14 *Association for Research in Vision and Ophthalmology Annual Meeting* will be held at the Broward County Convention Center in Ft. Lauderdale, FL. **Contact:** OSMC, 9650 Rockville Pike, Bethesda, MD 20814-3998.

Phone: 301-530-7009 ♦ Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org

16-20 “*New World Science for the Next Millennium*” sponsored by the American Society for Biochemistry and Molecular Biology, the Pan-American Society for Biochemistry, the Canadian Society of Biochemistry and Molecular and Cellular Biology and the Division of Biological Chemistry of the American Chemical Society. **Contact:** ASBMB Meeting Office, 9650 Rockville Pike, Bethesda, MD 20814-3998.

Phone: 301-530-7010 ♦ Fax: 301-530-7014
Email: gswindle@osmc.faseb.org
Web: www.faseb.org/meetings/jointmt.htm

26-30 *5th International Symposium on the Immunotherapy of the Rheumatic Diseases* will be held in Limassol, Cyprus. **Contact:** Symposium Secretariat, Dept. Of Rheum., 5th Fl., Thomas Guy House, Guy’s Hospital, London, UK SE1 9RT.
Phone: 44 171 955 4394 ♦ Fax: 44 171 955 2472
Email: s.dorward@umds.ac.uk

27-29 *Second Interleukin-10 Workshop* will be held in the San Raffaele Biomedical Science Park, Milan, Italy. **Contact:** Conference Secretariat, Elena Del Boca, Science Park RAF, Via Olgettina 58, 20132 Milano, Italy.
Phone: 39 02 2643 2454 ♦ Fax: 39 02 2643 3754
Email: delboca@spr.it
Web: www.gla.ac.uk/IL10-Workshop

30-Jun. 4 *Gordon Research Conference in Immunochemistry and Immunobiology* will be held at Il Ciocco in Barga, Italy.
Web: www.grc.uri.edu/99sched.htm
Online application: www.grc.uri.edu/attend.htm

JUNE

13-18 *The 58th Annual Meeting of the Society for Developmental Biology* will be held at the University of Virginia, Charlottesville, VA. Abstract deadline: March 12. **Contact:** SDB, 9650 Rockville Pike, Bethesda, MD 20814.
Fax: 301-571-5704
Email: adb@faseb.org
Web: www.sdb.bio.purdue.edu

17-19 *X Symposium on HIV Infection* will be held in Toulon, France. **Contact:** A. Conseil, 7 Boulevard de Corbevoie, 92521, Neuilly sur Seine, France.
Fax: 33 1 46 4070 36
Email: BERANGERE.ALBINE@wanadoo.fr

17-20 *7th European Meeting on Complement in Human Disease* will be held in Helsinki, Finland. **Contact:** Congress Secretariat, Complement in Human Disease, c/o Congrex Blue & White Conferences Oy, P.O. Box 81, Sulkapolku 3, 3rd Floor, FIN-00371 Helsinki, Finland.
Phone: 358 9 5607500 ♦ Fax: 358 9 56075020
Email: complement@bluewhite.conferences.fi
Web: www.complement.helsinki.fi

JULY

10-14 *The American Society for Virology 18th Annual Scientific Meeting* sponsored by the University of Massachusetts will be held in Amherst, MA. **Contact:** Dr. Sidney E. Grossberg, Secretary-Treasurer, Society for Virology, Dept. Of Microbiology and Molecular Genetics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53266-0509.

Phone: 414-456-8104 ♦ Fax: 414-456-6566
Email: segrossb@mcw.edu
Web: www.mcw.edu/asv/1999mtg.html

11-16 *FASEB Summer Research Conference on Phylogenetic Perspectives on the Vertebrate Immune System* will be held at Copper Mountain, Colorado. Meeting chairs: Gregory Beck, Manickam Sugumaran and Edwin L. Cooper. **Contact:** FASEB Summer Research Conferences, 9650 Rockville Pike, Bethesda, MD 20814-3998.
Fax: 301-571-0650
Email: ahewitt@faesb.org

17-23 *24th International Herpesvirus Workshop* will be held at the Massachusetts Institute of Technology. **Contact:** MIT Conference Services, Events and Information Center.
Phone: 617-253-1700 ♦ Fax: 617-258-7005
Email: conf-serv-www@mit.edu
Web: web.mit.edu/conf-serv/www/herpesvirusworkshop

19-21 *AAI Advanced Course in Immunology* will be held at the University of California-Berkeley. **Contact:** Linda Nelson, UC-San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0687.
Phone: 619-534-0625 ♦ Fax: 619-534-5611
Email: linda@biomail.ucsd.edu

24-28 *13th Symposium of The Protein Society* will be held at the John B. Hynes Veterans Memorial Convention Center in Boston, MA. **Contact:** OSMC, 9650 Rockville Pike, Bethesda, MD 20814-3998.
Phone: 301-530-7009 ♦ Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org

AUGUST

1-6 *13th International Conference on Lymphoid Tissues in Immune Reactions* (13th Germinal Center Conference) will be held in Geneva, Switzerland. **Contact:** Jacqueline Ntah, Conference Secretariat, 13th GCC, Dept. Of Pathology, University of Geneva, 1, rue Michel Servet, CH-1211 Geneva 4, Switzerland.
Phone: 41 22 702 57 45 ♦ Fax: 41 22 702 57 46
Email: jacqueline.ntah@medecine.unige.ch

23-26 *The Alfred Benzon Symposium No. 46: Molecular Mechanisms of Innate Immunity* will be held in Copenhagen, Denmark. **Contact:** Alfred Benzon Foundation, Strandvejen 203, DK-2900 Hellerup, Denmark, attn. Ms. Birgit Dalgaard.
Phone: 45 3962 0937 ♦ Fax: 45 3962 0933
Email: benzon@post1.tele.dk
Web: www.benzon-symposia.dk

SEPTEMBER

8-10 *The First International Congress on Cytokines and Chemokines in Infectious Diseases* will be held at the Natcher Conference Center on the NIH Campus in Bethesda, MD. This meeting is sponsored by The International Immunocompromised Host Society and The National Institute of Allergy and Infectious Diseases. **Contact:** 3224 Brooksong Way, Dacula, GA 30019.
Phone 770-271-8817 ♦ Fax: 770-271-3317
Email: wsnw@bellsouth.net
Web: www.ichs.org

8-10 *Seventh International Conference on Human Antibodies & Hybridomas* will be held at the Royal College of Physicians, Edinburgh, Scotland, UK. Sponsored by the International Journal Human Antibodies, in association with The Rajko Medenica Research Foundation. **Contact:** John Herriot, HAH'99, Meetings Management, Hart House, No. 4 The Hart, Farnham, Surrey, GU9 7HA, UK.

Phone: 44 (0)1252 726066 • Fax: 44 (0)01252 723303
Email: jherriot@meetingsmgmt.u-net.com

19-23 *Third European Symposium of The Protein Society* will be held in Garmisch-Partenkirchen, Germany. **Contact:** OSMC, 9650 Rockville Pike, Bethesda, MD 20814-3998.
Phone: 301-530-7009 • Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org

22-26 *The 15th International Congress of the Society for Leukocyte Biology* will be held at Churchill College, Cambridge University, UK. Abstract deadline: May 5, 1999. **Contact:** SLB, 9650 Rockville Pike, Bethesda, MD 20814.
Fax: 301-571-5704
Email: slb@faseb.org
Web: www.biosci.ohio-state.edu/~slb/

OCTOBER

8-10 *6th International Workshop on Langerhans Cells* will provide a forum for an exchange of ideas and information on the cutting edge of research on Langerhans cells (LC) and other dendritic antigen presenting cells. Topics include functions of LC/dendritic cells; host defenses; allergy, autoimmunity and tolerance; dendritic cells in disease; and molecular approaches and gene therapy. The meeting is organized by the Department of Dermatology at the Joan and Sanford I. Weill Med. Coll. at Cornell Univ. **Contact:** IWLC, 820 West Superior Ave., Suite 340, Cleveland, OH 44113-1800.
Phone: 216-579-9344 • Fax: 216-579-9333
Email: cockburn@sidnet.org

10-15 *Bat-Sheva Seminar on Innate Immunity* will be held at the Moriah Hotel in Zichron-Yaakov, Israel. **Contact:** InTour Travel Agency, Kiryat Ono, 3, Ha-Haganah St., PO Box 9095, Ramat-Gan 52190, Israel.
Phone: 972 3 6355038 • 972 3 6406098 • Fax: 972 3 5351103
Email: mrgzur@ibm.net or intour@ibm.net

DECEMBER

5-9 *7th Annual Meeting of the International Cytokine Society* will be held in Hilton Head, SC. The meeting covers a broad range of topics on cytokines from the lab to the clinic. Cytokines will include interleukins, hematopoietic factors, chemokines, interferons, the TNF family, TGFs and others. Processes will include cell biological topics of growth, differentiation, death, and roles in pathological processes and therapeutic applications relevant to cytokines. The program will be equally divided among invited speakers and submitted abstracts. **Contact:** ICS Headquarters, Biotech Park, Suite 9, 1021 15th St., Augusta, GA 30901.
Phone: 706-722-7511 • Fax: 706-722-7515
Email: maps@csranet.com

FUTURE MEETINGS

Jan. 9-12, 2000 *42nd Annual Clinical Conference & 52nd Annual Symposium on Cancer Research: Cancer Research at the Millennium* will be held at the Westin Galleria Hotel in Houston, Texas. **Contact:** Office of Conference Services, UT M.D. Anderson Cancer Center.
Phone: 713-792-2222 • Fax: 713-794-1724
Web: www.mdacc.tmc.edu/~meetings

May 11-17, 2000 *AAI Annual Meeting* will be held in Seattle, WA. **Contact:** AAI, 9650 Rockville Pike, Bethesda, MD 20814.
Phone: 300-530-7178 • Fax: 301-571-1813
Email: infoaai@aai.faseb.org
Web: www.scienceXchange.com/aai

Jul. 8-12, 2000 *The American Society for Virology 19th Annual Scientific Meeting* sponsored by the Colorado State Univ. will be held in Fort Collins, CO. **Contact:** Dr. Sidney E. Grossberg, Secretary-Treasurer, Society for Virology, Dept. Of Microbio. and Mole. Genetics, Med. Coll. of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53266-0509.
Phone: 414-456-8104 • Fax: 414-456-6566
Email: segrossb@mcw.edu

Jul. 23-27, 2000 *International Complement Workshop XVIII* will be held at the Snowbird Ski and Summer Resort, Salt Lake City, UT. **Contact:** Conferences & Institutes, Rm 2174, 1901 East South Campus Dr., Salt Lake City, UT 84112-9359.
Phone: 801-581-5809 • Fax: 801-581-3165
Email: confer@admin.dce.utah.edu
Web: www.conferences.utah.edu

Mar. 31-Apr. 4, 2001 *EB '2001* will be held in Orlando, FL. **Contact:** EB '2001, 9650 Rockville Pike, Bethesda, MD 20814.
Phone: 301-530-7010 • Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org/meetings

Apr. 13-17, 2002 *EB '2002* will be held in San Diego, CA. **Contact:** EB '2001, 9650 Rockville Pike, Bethesda, MD 20814.
Phone: 301-530-7010 • Fax: 301-530-7014
Email: eb@faseb.org
Web: www.faseb.org/meetings

Jul. 7-12, 2002 *XIVth World Congress of Pharmacology* sponsored by the International Union of Pharmacology, the National Academy of Sciences, U.S.A., and the American Society for Pharmacology and Experimental Therapeutics. Abstract deadline is January 31, 2002. **Contact:** Congress Secretariat, XIVth World Congress of Pharmacology, 9650 Rockville Pike, Bethesda, MD 20814-3995.
Phone: 301-530-7061
Email: juphar@aspet.faseb.org

The 1999 **Marine Biological Laboratory** (MBL) course schedule is now available. MBL is an independent, non-profit research and educational institution, located in Woods Hole, MA. MBL courses are generally designed for advanced graduate students and postdocs. Science writing courses are designed for professional journalists.

For application forms and information about MBL educational programs contact:

Carol Hamel
Admissions Coordinator
Marine Biological Laboratory
7 MBL Street
Woods Hole, MA 02543-1015
Phone: 508-289-7401
Email: admissions@mbl.edu
Web: www.mbl.edu

The 1999 **Jackson Laboratory** Courses and Conferences Program schedule is now available. For application forms and information about the Jackson Laboratory courses and conference programs contact:

Phone: 207-288-6262
Email: education@jax.org
Web: www.jax.org/courses

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE ♦ BETHESDA, MD 20814-3994

TEL: (301) 530-7178 ♦ FAX: (301) 571-1816

FEDERAL TAX ID NO: 04-2281787

Email Address: members@aai.faseb.org ♦ Website Address: http://www.scienceXchange.com/aai

QUALIFICATIONS AND APPLICATION FOR REGULAR MEMBERSHIP 1999 MEMBERSHIP YEAR

The American Association of Immunologists (AAI) is a professional organization whose members have a strong interest in, and have made substantial contributions to, the science of immunology. AAI is a member of the Federation of American Societies for Experimental Biology (FASEB) and is responsible for the publication of the *Journal of Immunology*. To be eligible for election to membership in the AAI, a candidate must meet **one** of the following criteria:

1. Possess a Ph.D., (or equivalent graduate degree, *e.g.*, D.Sc.) in immunology or related disciplines, or an M.D. (or equivalent medical degree, *e.g.*, D.D.S.) and be the **first** author of **one** significant original publication on an immunological topic in a reputable, refereed journal. Manuscripts "in press" are acceptable when accompanied by a letter from the publisher or Editor-In-Chief of the journal affirming its acceptance and imminent publication. Abstracts and unpublished papers **will not** be considered in evaluating whether a candidate meets the publications requirement for membership. The requirement for the Ph.D./M.D. can be waived in certain circumstances if the candidate shows evidence of other appropriate training and research experience.
2. Be an established scientist with substantial achievement in a related discipline and have at least one collaborative paper on an immunological topic in a reputable, refereed journal.

THIS APPLICATION MUST INCLUDE:

1. Four copies of your bibliography and curriculum vitae.
2. The name and signature of an active AAI member as your reference.

NAME: _____

DEGREE (YEAR) & INSTITUTION: _____

PUBLICATION: _____

CURRENT TITLE/POSITION: _____

ADDRESS: _____

STREET: _____

CITY: _____ STATE: _____ ZIP CODE: _____

E-MAIL ADDRESS: _____

PHONE#: () _____ FAX#: () _____

RESEARCH SPECIALTY: _____

REFERENCE:

NAME OF AAI MEMBER (*please print clearly*): _____

SIGNATURE OF AAI MEMBER: _____

Applications should be mailed to the AAI office and marked to the attention of the Chair of the AAI Membership Committee. Please **DO NOT** send payment with your application. You will be invoiced upon approval.

Applications received between **October 1** and **March 1** will be reviewed at the Spring Council Meeting. Applications received between **April 1** and **September 1** will be reviewed at the Fall Council Meeting.

1999 Dues Rates: 1 January - 31 December: **U.S. - \$225.00** **Canadian - \$323.00** **International - \$315.00**

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS

9650 ROCKVILLE PIKE • BETHESDA, MD 20814-3994

TEL: (301) 530-7178 • FAX: (301) 571-1816

FEDERAL TAX ID NO: 04-2281787

Email Address: members@aai.faseb.org • Website Address: http://www.scienceXchange.com/aai

1999 TRAINEE MEMBERSHIP APPLICATION FORM

Name: _____ Email Address: _____

Address: _____

City: _____ State: _____ Zip Code: _____

Phone Number: () _____ Fax Number: () _____

Students and Post-Doctoral Trainees may become Trainee members of the AAI. Trainee members will receive a subscription to the *Journal of Immunology* and the *AAI Newsletter*. **Subscriptions will start upon receipt of your application and end on December 31 of the current year.** Trainee members will also have the privilege of attending and participating (without vote) in the AAI Annual Business Meeting. In addition, they will receive all AAI announcements and correspondence.

Qualified applicants must complete the information below and return this form with the required payment. Checks are to be made payable to *The American Association of Immunologists*. All checks must be drawn on a U.S. bank and International money orders are accepted.

Individuals may remain Trainee members for a maximum of eight (8) years. Certification **must** be renewed annually.

PRE-DOCTORAL TRAINEE

POST-DOCTORAL TRAINEE

I hereby certify that _____

I hereby certify that _____

(Please print clearly)
is a regularly matriculated *student* in the Department of

(Please print clearly)
is a :post-Doctoral Trainee in the Department of

at _____
(University or Institution)

at _____
(University or Institution)

and as such is eligible to become a Pre-Doctoral Trainee member of the AAI.

and as such is eligible to become a Post-Doctoral Trainee member of the AAI.

(Signature- must be an AAI member)

(Signature- must be an AAI member)

Name _____
(Please print clearly)

Name _____
(Please print clearly)

Title _____
(Dean, Department Chair or Professor in Charge)

Title _____
(Dean, Department Chair or Professor in Charge)

Date _____

Date _____

PLEDGE

I _____, pledge that the copies of the *JOURNAL OF IMMUNOLOGY* received by me as an AAI Trainee member are for my personal use. They will not be placed in a library for general use, sold, or replace a subscription currently purchased by an institution.

1 JANUARY - 31 DECEMBER 1999

U.S. Member

Canadian Member

International Member

\$64.00

\$158.00 (7% GST Incl.)

\$154.00

CHECK ENCLOSED

VISA

MASTERCARD

CARD NUMBER: _____ EXPIRATION DATE: _____

SIGNATURE: _____

TO HELP REDUCE OUR CREDIT CARD PROCESSING FEES, WE WOULD APPRECIATE YOUR PAYMENT BY CHECK.

THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS
9650 ROCKVILLE PIKE BETHESDA, MARYLAND 20814-3994

Non Profit Org.
U.S. Postage
PAID
Bethesda, MD
Permit 1126